CLAIMS

1. A recombinant single chain polynucleotide comprising a region encoding the variable region of the light chain of an anti-G_{D2} antibody linked to a region encoding the variable region of the heavy chain of an anti-G_{D2} antibody.

2. The recombinant polynucleotide of claim 1, further comprising a region encoding an additional protein.

3. The recombinant polynucleotide of claim 1, wherein the additional protein is streptavidin.

4. The recombinant polynucleotide of claim 1, wherein the additional protein is a drug-converting enzyme.

5. A recombinant single chain peptide comprising the variable region of the light chain of an anti-G_{D2} antibody linked to the variable region of the heavy chain of an anti-G_{D2} antibody.

6. The peptide according to claim 5, wherein the peptide is labeled with a radiolabel.

7 The peptide according to claim 6, wherein the radiolabel is ^{99m}Tc.

8. The peptide according to claim 5, wherein the peptide further comprises a drug-converting enzyme.

9. The peptide according to claim 5, wherein the peptide further comprises streptavidin.

10. The peptide according to claim 5, wherein the peptide further comprises CD8.

11. T cells expressing a recombinant single chain peptide comprising the variable region of the light chain of an anti-G_{D2} antibody linked to the variable region of the heavy chain of an anti-G_{D2} antibody.

12. A method for assaying for the presence of cells expressing G_{D2} in tissue comprising combining the tissue with a recombinant single chain peptide comprising the variable region of the light chain of an anti-G_{D2} antibody linked to the variable region of the heavy chain of an anti-G_{D2} antibody and a detectable label.

13. A method for targeted delivery of a therapeutic agent to cells expressing G_{D2} in tissue comprising combining the tissue with a recombinant single chain peptide comprising the variable region of the light chain of an anti-G_{D2} antibody linked to the variable region of the heavy chain of an anti-G_{D2} antibody and a therapeutic or pre-therapeutic moiety.

14. The method according to claim 13, wherein the pre-therapeutic moiety is a pro-drug converting enzyme.

15. The method according to claim 13, wherein the pre-therapeutic moiety is streptavidin.

16. The method according to claim 13, wherein the therapeutic moiety is a toxin.